ACTRN12619000786190已完成未知
The Swedish Oesophageal and Cardia Cancer study
MMK Karolinska Institutet0 个研究点目标入组 616 人开始时间: 2019年5月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 616
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Operated for esophageal cancer in Sweden April 2001-December 2005.
排除标准
- •No exclusion criteria.
研究者
相似试验
已完成
不适用
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
进行中（未招募）
不适用
Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study - Feasibility trial of chemoradiation or surgery for oesophageal canceroesophageal cancerMedDRA version: 12Level: LLTClassification code 10030151Term: Oesophageal cancerEUCTR2009-013877-16-GBniversity Hospitals Bristol NHS Foundation Trust
尚未招募
不适用
Prospective Multicenter Observational Study of Esophageal Preservation Survival in definitive Chemoradiotherapy +/- Photodynamic Therapy for Esophageal CancerEsophageal CancerJPRN-UMIN000043767agoya University150
进行中（未招募）
1 期
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)oesophageal squamous cell carcinoma and oeasophageal adenocarcinomaMedDRA version: 20.0Level: PTClassification code 10061534Term: Oesophageal squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000053-53-ESEuropean Organisation for Research and Treatment of Cancer130
进行中（未招募）
1 期
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)EUCTR2018-000053-53-DEEuropean Organisation for Research and Treatment of Cancer130